Eli Lilly Enters Strategic Research Collaboration with Abbisko Therapeutics, Potential $1.9 Billion in Payments
Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment
Positive
Importance
7
Price
$1,107.48
Mkt Cap
$1.043T
52W Low
$623.78
52W High
$1,182.73
52W Position
78% above low
Off High
6.4% below high
Rel. Volume
1.0× avg
Market data snapshot near publication time
LLY sits 78% above its 52-week low of $623.78.
Summary
Eli Lilly has entered a strategic research collaboration and license agreement with Abbisko Therapeutics, focusing on multiple innovative medicine targets. Under the terms, Abbisko is eligible for payments up to $1.9 billion. This agreement expands Eli Lilly's R&D pipeline and potential future drug development.
At the time of this announcement, LLY was trading at $1,107.48 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.
Price Chart
LLY - Latest Insights
LLY
Oct 02, 2026, 3:05 PM EDT
Price at Filing:
$1,147.30
Real-time Price:
$1,143.60
Change:
-$3.70 (-0.32%)
Market Cap:
$1.076T
LLY
Oct 01, 2026, 7:01 AM EDT
Price at Filing:
$1,158.84
Real-time Price:
$1,143.60
Change:
-$15.24 (-1%)
Market Cap:
$1.076T
LLY
Sep 30, 2026, 6:29 PM EDT
Price at Filing:
$1,162.58
Real-time Price:
$1,143.60
Change:
-$18.97 (-2%)
Market Cap:
$1.076T
LLY
Sep 30, 2026, 10:15 AM EDT
Price at Filing:
$1,188.91
Real-time Price:
$1,143.60
Change:
-$45.30 (-4%)
Market Cap:
$1.076T
LLY
Sep 29, 2026, 8:01 AM EDT
Price at Filing:
$1,186.46
Real-time Price:
$1,143.60
Change:
-$42.86 (-4%)
Market Cap:
$1.076T